Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00378014
Status:
COMPLETED
Last Update Posted:
2015-02-06
First Post:
2006-09-15
Brief Title:
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy PROTECT Study A Twelve-month Multicenter Randomized Open-label Study of Safety Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to show that everolimus initiation together with reduction and thereafter discontinuation of calcineurin inhibitor CNI will improve significantly renal function in de novo liver transplant recipients as compared to continuation of CNI-based treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-002920-32 | None | None | None |